Introduction
============

Prevalence of obesity and type 2 diabetes mellitus (T2DM) in the pediatric population has increased worldwide \[[@b1-apem-2018-23-4-196],[@b2-apem-2018-23-4-196]\]. The same phenomena have been observed in Korean children and adolescents \[[@b3-apem-2018-23-4-196],[@b4-apem-2018-23-4-196]\]. Comorbidities of obesity and complications of T2DM have become important issues in the pediatric population \[[@b5-apem-2018-23-4-196],[@b6-apem-2018-23-4-196]\]. Therefore, prevention of pediatric obesity and T2DM is critical for reducing the burden of these health problems \[[@b1-apem-2018-23-4-196],[@b7-apem-2018-23-4-196]\]. For the earlier intervention, there have been studies conducted for developing and evaluating the markers for these cardiometabolic risk factors (CMRFs) associated with obesity and T2DM \[[@b8-apem-2018-23-4-196],[@b9-apem-2018-23-4-196]\].

Glycated hemoglobin (HbA1~c~) is an index that reflects the mean blood glucose for the prior 2--3 months and is a gold standard for controlling blood glucose among patients with diabetes mellitus (DM) \[[@b10-apem-2018-23-4-196],[@b11-apem-2018-23-4-196]\]. However, some studies have reported differences in HbA1~c~ in patients with similar mean blood glucose levels \[[@b12-apem-2018-23-4-196],[@b13-apem-2018-23-4-196]\]. Approximately 60%--80% of the HbA1~c~ variance could be explained by mean blood glucose levels, while the rest is influenced by ethnic and genetic factors \[[@b14-apem-2018-23-4-196],[@b15-apem-2018-23-4-196]\], glucose metabolism, and biological factors involved in hemoglobin glycation \[[@b16-apem-2018-23-4-196]\]. A statistical method to quantify the difference between predicted and actual HbA1~c~ levels was provided by Hempe et al. \[[@b17-apem-2018-23-4-196]\], which was termed hemoglobin glycation index (HGI). HGI is defined as the value obtained by subtracting predicted HbA1~c~ from measured HbA1~c~. Predicted HbA1~c~ is calculated by using equations from linear regression of HbA1~c~ and fasting blood glucose. When HGI is high or low, it means that the measured HbA1~c~ is higher or lower than the predicted HbA1~c~ at the blood glucose level. HGI indicates the degree of nonenzymatic glycation of hemoglobin, which has been positively correlated with complications of DM \[[@b18-apem-2018-23-4-196],[@b19-apem-2018-23-4-196]\]. Moreover, a recent study revealed that HGI is associated with hepatic steatosis in adults without DM, and is considered an emerging risk factor for metabolic syndrome (MS) and future T2DM \[[@b20-apem-2018-23-4-196]\].

However, to date, only one study has been reported about HGI in children with type 1 diabetes mellitus (T1DM), which showed HGI as a robust measure of HbA1~c~ bias \[[@b21-apem-2018-23-4-196]\]. Further, no studies have been performed on the association between HGI and CMRFs in the pediatric population without DM. Therefore, the aim of this study was to describe the distribution of HGI and to investigate the correlation of HGI with MS, its components, and alanine aminotransferase (ALT) as an index of nonalcoholic fatty liver disease (NAFLD) in a pediatric nondiabetic population.

Materials and methods
=====================

1. Study subjects
-----------------

This study was based on data from the Korea National Health and Nutrition Examination Survey (KNHANES) 2011--2016. This cross-sectional nationwide survey, conducted by the Korea Centers for Disease Control and Prevention (KCDC), used a multistage, stratified, and clustered probability sampling method to select a representative sample of the Korean civilian population. Of the total 47,164 participants, children and adolescents aged between 10 and 18 years were selected (n=5,043). Exclusion criteria were as follows: subjects who fasted less than 8 hours before blood sampling (n=553); absence of results of fasting glucose or elevated fasting glucose values of ≥126 mg/dL (n=1,050); absence of results of HbA1~c~ or elevated HbA1~c~ of ≥6.5% (n=1,074); previously diagnosed DM (n=3); pregnancy (n=0); absence of any component of MS (n=1,105), and absence of anthropometric measurements (n=382). Finally, 3,885 participants (2,074 young males and 1,811 young females) were eligible for the analysis ([Fig. 1](#f1-apem-2018-23-4-196){ref-type="fig"}).

2. Anthropometric and laboratory data
-------------------------------------

Anthropometric measurements were performed on all participants by trained personnel. Height was measured to the nearest 0.1 cm by using a stadiometer (Seca 225, Seca, Hamburg, Germany). Weight was measured by using an electronic balance (GL-600020, G-tech, Seoul, Korea) to the nearest 0.1 kg, and body mass index (BMI) was calculated as weight (kg) divided by height squared (m^2^). Height and BMI were transformed into z-scores by using the 2017 Korean National Growth Charts \[[@b22-apem-2018-23-4-196]\]. Waist circumference (WC) was measured to the nearest 0.1 cm by using a flexible tape measure, from the midpoint between the lowest border of the rib cage and the uppermost border of the iliac crest at the end of expiration (Seca 220, Seca). Blood pressure (BP) was measured by using a mercury sphygmomanometer (Baumanometer Desk model 0320 in 2011--2012 and Baumanometer Wall Unit 33\[0850\] in 2013--2016, Baum, NY, USA) on the right arm after the subject had rested for at least 5 minutes in a seated position. BP was measured 3 times, and the mean of the last 2 values were used for the analyses.

Fasting blood samples were collected from each participant by trained medical personnel. Plasma glucose, total cholesterol, high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), aspartate aminotransferase, and ALT were measured by using a Hitachi Automatic Analyzer 7600 (Hitachi, Tokyo, Japan). The level of HbA1~c~ was measured by using high performance liquid chromatography (HLC-723G7, Tosoh, Tokyo, Japan), which was the certified method by the National Glycohemoglobin Standardization Program. All laboratory tests were performed in the Central Laboratory.

3. Definition of HGI and MS
---------------------------

HGI was defined as the difference between measured HbA1~c~ and predicted HbA1~c~ (HGI=measured HbA1~c~--predicted HbA1~c~). Predicted HbA1~c~ was calculated by using the following formula through individual measurements of fasting plasma glucose (FPG), which were derived from linear regression analysis of measured HbA1~c~ and fasting glucose (HbA1~c~ (%)=0.0089×FPG \[mg/dL\]+4.6173 \[R-squared=0.0466, *P*\<0.001\]) ([Fig. 2](#f2-apem-2018-23-4-196){ref-type="fig"}). Study subjects were classified into 3 groups according to the tertile of HGI.

MS was defined by using the International Diabetes Federation criteria \[[@b23-apem-2018-23-4-196]\]. MS was confirmed, when a subject had abdominal obesity with 2 or more abnormalities in the following 4 measurements: TG, HDL-C, BP, and FPG. Abdominal obesity was defined when WC was ≥90th percentile in those aged 10--15 years or WC was ≥90 cm in males and ≥85 cm in females aged 16--18 years. Abnormal results were defined as follows: systolic or diastolic BP≥130/85 mmHg, FPG≥100 mg/dL, TG≥150 mg/dL, HDL-C\<40 mg/dL in males aged 10--18 years and females aged 10--15 years, and \<50 mg/dL in females aged between 16 and 18 years. CMRF clustering was defined as the presence of ≥2 abnormal components of MS \[[@b8-apem-2018-23-4-196],[@b24-apem-2018-23-4-196]\]. ALT was used as a marker for NAFLD in a pediatric population \[[@b25-apem-2018-23-4-196]\]. ALT elevation was defined as ≥30 IU/L for males and ≥19 IU/L for females \[[@b26-apem-2018-23-4-196],[@b27-apem-2018-23-4-196]\].

4. Statistical analysis
-----------------------

Data were analyzed using Stata 14.2 (StataCorp LP, College Station, TX, USA) with svy commands appropriate for the KNHANES sampling design. Data were expressed as the means±standard error for continuous variables or number of subjects (weighted percent) for categorical variables. Linear regression analysis was used to calculate predicted HGI values. Clinical characteristics were compared between tertiles of HGI by using the Student *t*-test or regression analysis for continuous variables, or logistic regression analysis and chi-square test for categorical variables. *P*-value for comparison between tertiles and *P* for trend from the lower to the upper HGI tertiles were obtained. Multiple logistic regression analysis was performed to determine the odds ratio (OR) with 95% confidence interval (CI) for association between HGI and components of MS and elevated ALT with adjustment for hemoglobin and BMI z-score. Further multiple logistic regression analyses were performed to identify association between HGI and CMRF clustering, MS and ALT elevation, after stratification by sex, age group (10--14 years and 15--18 years) and BMI category (normal weight and overweight/obese). Association between HGI and CMRFs were analyzed using simple and multiple linear regression analysis adjusting hemoglobin and BMI *z*-score. Due to the multicollinearity, HbA1~c~ and HGI was not used in the same analysis. A *P* value of \<0.05 was considered statistically significant.

5. Ethics statement
-------------------

The KNHANES was approved by the Institutional Review Board of the KCDC (2011-02CON-06-C, 2012-01EXP-01-2C, 2013-07CON-03-4C, 2013-12EXP-03-5C). Written informed consent was obtained from all participants prior to the survey. The present study was approved by the Institutional Review Board of the Seoul National University Bundang Hospital (approval number: X-1807/483-902).

Results
=======

1. Clinical characteristics of study participants by HGI tertiles
-----------------------------------------------------------------

The mean of HGI (%) was 0.000±0.006, with a range of between -1.887 and 1.002. The mean and range of HGI by lower (HGI-T1), mid (HGI-T2), and upper (HGI-T3) tertiles were -0.277±0.006 (-1.887 to -0.107), 0.000±0.005 (-0.105 to 0.111), and 0.280±0.005 (0.113 to 1.002), respectively. The cumulative proportion of HGI according to measured HbA1~c~ is presented in [Fig. 3](#f3-apem-2018-23-4-196){ref-type="fig"}.

The anthropometric and metabolic characteristics of study participants according to tertiles of HGI values are shown in [Table 1](#t1-apem-2018-23-4-196){ref-type="table"}. The mean age was 14.3±0.1 years, and 53.6% of participants were males. Overweight or obese subjects were 19.9% (n=768). Participants were divided into 2 age groups; 10--14 years (n=2,253, 48.8%) and 15--18 years (n=1,632, 51.2%). No significant differences between the groups were observed for age, sex, height z-scores, and WC. BMI z-scores and proportion of obesity increased with respect to HGI tertile. Subjects in higher HGI tertiles had higher values of HbA1~c~, without differences in FPG. Serum level of total cholesterol and ALT statistically significantly increased with increasing HGI ([Table 1](#t1-apem-2018-23-4-196){ref-type="table"}). Proportion of abdominal obesity, elevated TG, and CMRF clustering showed an increasing tendency with respect to HGI tertile ([Fig. 4](#f4-apem-2018-23-4-196){ref-type="fig"}). However, proportion of MS, hyperglycemia, high BP, low HDL-C, and elevated ALT did not reveal differences among the groups ([Fig. 4](#f4-apem-2018-23-4-196){ref-type="fig"}).

2. Association between HGI and components of MS
-----------------------------------------------

There was no significant difference in components of MS and elevated ALT between HGI-T1 and HGI-T2 ([Table 2](#t2-apem-2018-23-4-196){ref-type="table"}). However, adjusted OR (95% CI) of elevated TG in HGI-T3 as compared with that in HGI-T1 was 1.65 (1.18--2.30). Other components, including MS and elevated ALT, did not show statistical significance.

In linear regression analysis, BMI z-score, HbA1~c~, TG, and ALT showed a significant positive association with HGI after adjusting BMI z-score and hemoglobin ([Table 3](#t3-apem-2018-23-4-196){ref-type="table"}). WC, BP, FPG, and HDL-C were not associated with HGI.

When stratified according to sex, age group, and BMI category, those overweight and obese showed increased OR for predicting CMRF clustering and ALT elevation with respect to the HGI ([Table 4](#t4-apem-2018-23-4-196){ref-type="table"}). OR (95% CI) for predicting CMRF clustering and ALT elevation in overweight/obese participants was 2.92 (1.47--5.80) and 2.72 (1.24--5.98), respectively. However, HGI was not significant for predicting MS.

Discussion
==========

In this cross-sectional study of Korean adolescents, HGI was associated with CMRFs. BMI z-score, HbA1~c~, TG, and ALT levels showed linear correlation with HGI. Moreover, elevated TG was independently associated with HGI levels after adjusting for BMI z-score and hemoglobin. In overweight/obese subjects, HGI was associated with CMRF clustering and elevated ALT.

People with consistently higher or lower HbA1~c~ values than their glucose values have been classified as high and low glycators, respectively. HGI is a quantification of the difference between measured HbA1~c~ and predicted HbA1~c~, which is thought to represent the difference in glycation of hemoglobin among people with the same FPG. In T1DM patients, the higher the HGI level, the more microvascular complications such as retinopathy and nephropathy have been observed \[[@b28-apem-2018-23-4-196]\]. Moreover, a correlation between glycation gap and micro- and macrovascular complications has been reported in patients with T2DM \[[@b29-apem-2018-23-4-196]\]. One recent study reported that the higher the HGI level was, the higher was the risk of atherosclerosis and coronary artery calcification, which is a cardiovascular disease risk, even in nondiabetic adults \[[@b19-apem-2018-23-4-196]\]. These data support the fact that nonenzymatic protein glycation is one of the key players in explaining micro- and macrovascular complications associated with hyperglycemia. To the best of the authors\' knowledge, the present study is the first study to investigate the clinical relevance of HGI and association between HGI and CMRFs and ALT in the pediatric non-diabetic population by using nationally representative data.

MS is a combination of 3 out of 5 risk factors, such as abdominal obesity, elevated BP, high fasting glucose, high TG, and low HDL-C. A better understanding of the metabolic abnormalities in adolescence could lead to preventive interventions that could improve adolescents\' health outcomes and contribute to a reduction in cardiovascular disease in adults \[[@b30-apem-2018-23-4-196],[@b31-apem-2018-23-4-196]\]. In recent years, concerns have been raised about issues with difficulties in defining and applying MS to youth in clinical practice, therefore, it is important to individually evaluate and manage these cases with a focus to CMRF clustering \[[@b24-apem-2018-23-4-196]\].

In the present study, TG was associated with HGI. High TG levels were observed in the state with decreased insulin sensitivity, which was related to glucose metabolism in muscles \[[@b32-apem-2018-23-4-196],[@b33-apem-2018-23-4-196]\]. HGI might be associated with the insulin resistance, which was an underlying mechanism of MS \[[@b24-apem-2018-23-4-196]\]. The relationship between HGI and MS was not significant, although HGI and CMRF clustering were significantly associated. This suggests that the duration of exposure to higher levels of glucose or variation of glucose levels were relatively short and small in early childhood and adolescent periods for the occurrence of metabolic derangements. It might the affect the numbers of CMRFs in the study participants.

Overweight/obese subjects showed significant correlation between HGI and CMRF clustering, although HGI was not significantly different between groups by BMI category (normal weight -0.005 versus overweight/obese 0.018, P=0.052). Overweight/obese youth with higher HGI might have the more active the intracellular protein glycation process than those with normal weight, which could make difference in association with CMRF clustering according to BMI category. Therefore, HGI might be an alternative marker for an increased cardiometabolic risk in the pediatric population.

NAFLD has become a significant cause of chronic liver disease in childhood. It is associated with obesity, which might be considered as hepatic manifestation of MS \[[@b34-apem-2018-23-4-196]\]. Although liver biopsy has been considered the gold standard for diagnosing NAFLD, its invasiveness frequently makes it difficult to perform \[[@b25-apem-2018-23-4-196]\]. Currently, ALT is used as a surrogate marker of NAFLD. In a recent study, a correlation was found between elevated ALT (\>30 IU/L for males and \>19 IU/L for females) and MS and insulin resistance in Korean adolescents \[[@b26-apem-2018-23-4-196]\]. In adults, high HGI was associated with hepatic steatosis in nondiabetic population \[[@b20-apem-2018-23-4-196]\]. In the present study, ALT was associated with higher HGI values in overweight/obese group. Further study is required to elucidate the association between HGI and NAFLD in pediatric population.

The limitation of this study is that its design was crosssectional, making it difficult to understand the causal relationship. However, the present study is the first study to investigate the clinical relevance of HGI and to evaluate the association between HGI and CMRFs and ALT in the pediatric nondiabetic population by using nationally representative data.

In this study, HGI was associated with CMRFs, including BMI z-scores, obesity, total cholesterol, ALT, abdominal obesity, elevated TG levels, and CMRF clustering in a pediatric nondiabetic population. When stratified for sex, age group, and BMI category, overweight/obese subjects showed linear trends for the presence of CMRF clustering and ALT elevation with respect to increases in HGI. We, therefore, suggest that there is a possibility that HGI might be used as an alternative marker for cardiovascular diseases in a pediatric population. However, further longitudinal studies are warranted to investigate clinical implications of HGI in children and adolescents.
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###### 

Clinical characteristics of study participants

  Characteristic                           Total             HGI-T1             HGI-T2              HGI-T3              *P*-value   *P* for trend
  ---------------------------------------- ----------------- ------------------ ------------------- ------------------- ----------- ---------------
  No. of participants                      3,885 (100)       1,247 (34.1)       1,280 (32.7)        1,358 (33.3)                    
  HGI (%)                                                                                                               \<0.001     \<0.001
   Mean±SE                                 0.000±0.006       -0.277±0.005       0.004±0.002^\*\*^   0.280±0.005^\*\*^               
   Range                                   -1.887 to 1.002   -1.887 to -0.107   -0.105 to 0.111     0.113 to 1.002                  
  Age (yr)                                 14.3±0.1          14.4±0.1           14.3±0.1            14.3±0.1            0.468       0.309
  Sex, boys                                2,074 (53.6)      645 (51.8)         706 (55.5)          723 (53.4)          0.269       0.488
  Height *z*-score                         0.20±0.02         0.13±0.04          0.25±0.04           0.22±0.04           0.064       0.066
  BMI *z*-score                            0.00±0.02         -0.05±0.04         -0.04±0.04          0.09±0.05           0.060       0.030
  Waist circumference (cm)                 70.3±0.2          70.2±0.3           70.1±0.3            70.6±0.4            0.503       0.330
  BMI category                                                                                                          0.034       0.003
   Obesity                                 403 (10.9)        108 (8.8)          127 (10.5)          168 (13.2)                      
   Overweight                              365 (9.0)         115 (9.8)          116 (8.5)           134 (8.9)                       
   Normal                                  3,117 (80.1)      1,024 (81.4)       1,037 (81.0)        1,056 (77.9)                    
  Systolic BP (mmHg)                       107.9±0.2         108.3±0.3          107.7±0.3           107.7±0.3           0.316       0.203
  Diastolic BP (mmHg)                      66.3±0.2          66.4±0.3           66.0±0.3            66.2±0.4            0.565       0.443
  Fasting glucose (mg/dL)                  90.2±0.1          90.3±0.2           90.1±0.2            90.3±0.2            0.613       0.936
  HbA1~c~ (%)                              5.418±0.006       5.141±0.006        5.420±0.003^\*\*^   5.689±0.005^\*\*^   \<0.001     \<0.001
  Hemoglobin (g/L)                         14.12±0.03        14.23±0.04         14.17±0.04          13.94±0.05          0.244       \<0.001
  Total cholesterol (mg/dL)                157.0±0.5         155.0±0.9          156.9±0.9           159.1±0.9^\*\*^     0.006       0.001
  Triglyceride (mg/dL)                     73.9±0.8          72.9±1.2           73.9±1.2            75.1±1.4            0.449       0.207
  HDL-C (mg/dL)                            50.8±0.2          50.6±0.3           50.7±0.4            51.0±0.4            0.770       0.474
  AST (IU/L)                               18.9±0.2          18.6±0.2           19.1±0.4            19.1±0.2            0.217       0.131
  ALT (IU/L)                               15.2±0.3          14.2±0.3           15.7±0.7^\*^        15.7±0.5^\*^        0.016       0.015
  Elevated ALT                             280 (8.5)         80 (6.4)           90 (7.1)            110 (8.5)           0.189       0.082
  Abdominal obesity                        383 (10.7)        106 (9.1)          127 (10.4)          150 (12.6)          0.059       0.022
  Hyperglycemia                            312 (8.0)         103 (8.5)          102 (7.5)           107 (7.9)           0.699       0.600
  High blood pressure                      126 (3.5)         39 (3.1)           40 (3.5)            47 (3.9)            0.681       0.378
  Elevated triglyceride                    295 (8.1)         73 (6.3)           95 (7.8)            127 (10.2)          0.005       0.001
  Low HDL-C                                578 (15.8)        196 (16.7)         180 (15.1)          202 (15.6)          0.656       0.545
  Cardiometabolic risk factor clustering   346 (9.5)         99 (8.4)           108 (8.8)           139 (11.4)          0.046       0.027
  Metabolic syndrome                       72 (2.2)          21 (1.8)           16 (1.7)            35 (3.0)            0.120       0.098

Values are presented as number (weighted percent) or mean±standard error.

*P*-value was calculated for comparison between HGI-T1 and HGI-T2/T3 (^\*^*P*\<0.05, ^\*\*^*P*\<0.01).

P for trend was calculated using linear trend from HGI-T1 to HGI-T3.

HGI, hemoglobin glycation index; HGI-T1, lower tertile of HGI; HGI-T2, mid tertile of HGI; HGI-T3, upper tertile of HGI; BMI, body mass index; BP, blood pressure; HbA1~c~, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; AST aspartate aminotransferase; ALT, alanine aminotransferase.

###### 

Association between HGI tertiles and cardiometabolic risk factors

  Variable                                                             HGI-T1 vs. HGI-T2   HGI-T1 vs. HGI-T3                       
  -------------------------------------------------------------------- ------------------- ------------------- ------------------- -------
  Abdominal obesity                                                                                                                
   Univariate                                                          1.16 (0.86--1.57)   0.325               1.43 (1.05--1.95)   0.022
   Multivariate^[\*](#tfn1-apem-2018-23-4-196){ref-type="table-fn"}^   1.04 (0.64--1.71)   0.873               1.45 (1.07--1.97)   0.488
  Hypertension                                                                                                                     
   Univariate                                                          1.12 (0.68--1.84)   0.660               1.25 (0.76--2.04)   0.377
   Multivariate^[\*](#tfn1-apem-2018-23-4-196){ref-type="table-fn"}^   1.17 (0.69--1.97)   0.554               1.33 (0.79--2.26)   0.286
  Elevated plasma glucose                                                                                                          
   Univariate                                                          0.87 (0.63--1.21)   0.411               0.92 (0.66--1.28)   0.603
   Multivariate^[\*](#tfn1-apem-2018-23-4-196){ref-type="table-fn"}^   0.87 (0.62--1.21)   0.399               0.89 (0.64--1.24)   0.494
  Elevated triglyceride                                                                                                            
   Univariate                                                          1.26 (0.89--1.78)   0.187               1.71 (1.23--2.36)   0.001
   Multivariate^[\*](#tfn1-apem-2018-23-4-196){ref-type="table-fn"}^   1.26 (0.88--1.80)   0.208               1.65 (1.18--2.30)   0.003
  Decreased HDL-C                                                                                                                  
   Univariate                                                          0.89 (0.70--1.14)   0.360               0.92 (0.72--1.19)   0.548
   Multivariate^[\*](#tfn1-apem-2018-23-4-196){ref-type="table-fn"}^   0.86 (0.67. 1.11)   0.258               0.80 (0.62--1.04)   0.092
  CMRF clustering                                                                                                                  
   Univariate                                                          1.05 (0.77--1.43)   0.756               1.41 (1.04--1.90)   0.027
   Multivariate^[\*](#tfn1-apem-2018-23-4-196){ref-type="table-fn"}^   0.98 (0.69--1.39)   0.899               1.15 (0.83--1.61)   0.386
  Metabolic syndrome                                                                                                               
   Univariate                                                          0.92 (0.44--1.96)   0.837               1.68 (0.91--3.11)   0.097
   Multivariate^[\*](#tfn1-apem-2018-23-4-196){ref-type="table-fn"}^   0.77 (0.31--1.96)   0.589               1.09 (0.51--1.96)   0.832
  Elevated ALT                                                                                                                     
   Univariate                                                          1.12 (0.80--1.58)   0.502               1.34 (0.96--1.95)   0.081
   Multivariate^[\*](#tfn1-apem-2018-23-4-196){ref-type="table-fn"}^   1.18 (0.75--1.57)   0.657               1.18 (0.80--1.74)   0.393

HGI, hemoglobin glycation index; HGI-T1, lower tertile of HGI; HGI-T2, mid tertile of HGI; HGI-T3, upper tertile of HGI; OR, odds ratio; CI, confidence interval; HDL-C, high-density lipoprotein cholesterol; CMRF, cardiometabolic risk factor; ALT, alanine aminotransferase.

Adjusted for body mass index *z*-score and hemoglobin.

###### 

Association between HGI and cardiometabolic risk factors

  HGI                               Univariate       Multivariate^[\*](#tfn2-apem-2018-23-4-196){ref-type="table-fn"}^                    
  --------------------------------- ---------------- ------------------------------------------------------------------- ---------------- ---------
  Waist circumference (cm)          0.915 (0.706)    0.195                                                               0.283 (0.354)    0.425
  BMI *z*-score                     0.653 (0.270)    0.016                                                               0.923 (0.276)    \<0.001
  Systolic blood pressure (mmHg)    -0.716 (0.724)   0.324                                                               -0.166 (0.688)   0.809
  Diastolic blood pressure (mmHg)   -0.468 (0.718)   0.515                                                               0.146 (0.708)    0.836
  fasting plasma glucose (mg/dL)    -0.001 (0.503)   0.998                                                               -0.136 (0.501)   0.785
  Glycated hemoglobin (%)           0.999 (0.004)    \<0.001                                                             0.999 (0.004)    \<0.001
  Triglyceride (mg/dL)              0.078 (0.037)    0.037                                                               0.076 (0.035)    0.031
  HDL-C (mg/dL)                     0.016 (0.015)    0.283                                                               0.014 (0.015)    0.344
  ALT (IU/L)                        0.096 (0.036)    0.008                                                               0.113 (0.031)    \<0.001

Triglyceride, HDL-C, and ALT was log-transformed for the analysis.

HGI, hemoglobin glycation index; SE, standard error; BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; ALT, alanine aminotransferase.

Adjusted for BMI *z*-score and hemoglobin.

###### 

Association between HGI and CMRF clustering, metabolic syndrome, and ALT elevation according to sex, age group, and BMI category

  Variable                CMRF clustering     Metabolic syndrome   ALT elevation                                   
  ----------------------- ------------------- -------------------- ------------------- ------- ------------------- -------
  Sex                                                                                                              
   Boys                   0.79 (0.42--1.51)   0.476                0.88 (0.16--4.89)   0.886   1.42 (0.60--3.32)   0.424
   Girls                  2.38 (0.98--5.74)   0.054                1.06 (0.16--6.80)   0.953   1.29 (0.54--3.10)   0.180
  Age (yr)                                                                                                         
   10--14                 1.18 (0.57--2.44)   0.650                1.34 (0.22--8.05)   0.751   1.04 (0.47--2.30)   0.913
   15--18                 1.47 (0.66--3.29)   0.349                0.80 (0.15--4.26)   0.797   1.56 (0.65--3.76)   0.323
  BMI category                                                                                                     
   Normal                 0.91 (0.40--2.03)   0.812                1.36 (0.03--72.3)   0.880   0.90 (0.39--2.08)   0.804
   Overweight and obese   2.92 (1.47--5.80)   0.002                1.77 (0.56--5.61)   0.330   2.72 (1.24--5.98)   0.013

HGI, hemoglobin glycation index; CMRF, cardiometabolic risk factor; ALT, alanine aminotransferase; BMI, body mass index; OR, odds ratio; CI, confidence interval.

Adjusted for sex, age group, BMI category, and hemoglobin.
